Literature DB >> 12028745

Naltrexone and dysphoria: fact or myth?

Karen Miotto1, Michael McCann, Janice Basch, Richard Rawson, Walter Ling.   

Abstract

Naltrexone is an opiate antagonist used as a pharmacologic adjuvant for the treatment of opiate and alcohol addiction. It has been hypothesized that naltrexone blocks the stress-response and well-being effects associated with opioid peptides. This raises the clinical concern that naltrexone may cause dysphoria. The authors reviewed pharmacological and clinical data in alcohol, opioid, and nicotine studies to determine if an association between naltrexone and dysphoria exists. These studies did not reveal dysphoria to be a serious side effect produced by naltrexone treatment. Additional studies to evaluate long-term endocrine effects and antidepressant combination therapy are warranted.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12028745     DOI: 10.1080/10550490290087929

Source DB:  PubMed          Journal:  Am J Addict        ISSN: 1055-0496


  27 in total

Review 1.  Clinical safety of 1500 mg oral naltrexone overdose.

Authors:  Albert Stuart Reece
Journal:  BMJ Case Rep       Date:  2010-09-07

2.  Differential involvement of endogenous opioids in sucrose consumption and food reinforcement.

Authors:  Michael D Hayward; Alexandra Schaich-Borg; John E Pintar; Malcolm J Low
Journal:  Pharmacol Biochem Behav       Date:  2006-12-12       Impact factor: 3.533

Review 3.  Naltrexone efficacy in treating alcohol-use disorder in individuals with comorbid psychosis: a systematic review.

Authors:  Martyna Sawicka; Derek K Tracy
Journal:  Ther Adv Psychopharmacol       Date:  2017-05-24

4.  Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism.

Authors:  Nolan R Williams; Boris D Heifets; Brandon S Bentzley; Christine Blasey; Keith D Sudheimer; Jessica Hawkins; David M Lyons; Alan F Schatzberg
Journal:  Mol Psychiatry       Date:  2019-08-29       Impact factor: 15.992

5.  Binding mode characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives via docking in opioid receptor crystal structures and site-directed mutagenesis studies: application of the 'message-address' concept in development of mu opioid receptor selective antagonists.

Authors:  Saheem A Zaidi; Christopher K Arnatt; Hengjun He; Dana E Selley; Philip D Mosier; Glen E Kellogg; Yan Zhang
Journal:  Bioorg Med Chem       Date:  2013-09-04       Impact factor: 3.641

6.  In vitro and in vivo functional profile characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3-carboxamido)morphinan (NAQ) as a low efficacy mu opioid receptor modulator.

Authors:  Samuel Obeng; Yunyun Yuan; Abdulmajeed Jali; Dana E Selley; Yan Zhang
Journal:  Eur J Pharmacol       Date:  2018-03-09       Impact factor: 4.432

7.  Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) as a mu opioid receptor selective ligand.

Authors:  Yan Zhang; Amanda Braithwaite; Yunyun Yuan; John M Streicher; Edward J Bilsky
Journal:  Eur J Pharmacol       Date:  2014-05-08       Impact factor: 4.432

Review 8.  Opioid dependence treatment: options in pharmacotherapy.

Authors:  Angela L Stotts; Carrie L Dodrill; Thomas R Kosten
Journal:  Expert Opin Pharmacother       Date:  2009-08       Impact factor: 3.889

9.  Pharmacological characterization of 17-cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-6-[(3'-fluoro-4'-pyridyl)acetamido]morphinan (NFP) as a dual selective MOR/KOR ligand with potential applications in treating opioid use disorder.

Authors:  Yi Zheng; Samuel Obeng; Bethany A Reinecke; Chongguang Chen; Palak S Phansalkar; David M Walentiny; Phillip M Gerk; Lee-Yuan Liu-Chen; Dana E Selley; Patrick M Beardsley; Yan Zhang
Journal:  Eur J Pharmacol       Date:  2019-11-16       Impact factor: 4.432

10.  Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence.

Authors:  Angela J Dean; John B Saunders; Rod T Jones; Ross M Young; Jason P Connor; Bruce R Lawford
Journal:  J Psychiatry Neurosci       Date:  2006-01       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.